INT96148

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.72
First Reported 2001
Last Reported 2007
Negated 1
Speculated 2
Reported most in Body
Documents 3
Total Number 24
Disease Relevance 17.33
Pain Relevance 3.99

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
saliva 9
L368 2
sweat 2
urine 2
monocytes 1
HLA-S (Homo sapiens)
Pain Link Frequency Relevance Heat
Multiple sclerosis 560 99.84 Very High Very High Very High
Chronic pancreatitis 4 96.60 Very High Very High Very High
Inflammation 20 90.00 High High
Neuritis 20 86.24 High High
rheumatoid arthritis 20 80.36 Quite High
corticosteroid 20 80.32 Quite High
imagery 40 53.76 Quite High
Disease Link Frequency Relevance Heat
Demyelinating Disease 580 99.84 Very High Very High Very High
Pancreatic Cancer 32 99.60 Very High Very High Very High
Malignant Neoplastic Disease 8 99.60 Very High Very High Very High
Disease 276 99.50 Very High Very High Very High
Systemic Lupus Erythematosus 40 98.46 Very High Very High Very High
Pancreatitis 4 96.60 Very High Very High Very High
Cholangiocarcinoma 4 96.16 Very High Very High Very High
Organ Transplantation 4 96.00 Very High Very High Very High
Hepatocellular Cancer 8 95.36 Very High Very High Very High
Gallbladder Neoplasms 8 94.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
To examine the role of sHLA-I in the immune system of patients with malignancy, we examined serum sHLA-I levels in patients with pancreatic, biliary, hepatic malignancy, and other diseases.
Spec (examined) Gene_expression (levels) of sHLA-I in immune system associated with malignant neoplastic disease and disease
1) Confidence 0.72 Published 2001 Journal Hum. Immunol. Section Abstract Doc Link 11390036 Disease Relevance 1.08 Pain Relevance 0.08
Serum levels of sHLA-I in pancreatic cancer patients were higher than in the other diseases, although we found that pancreatic cancer cell lines did not produce the sHLA-I.
Neg (not) Gene_expression (produce) of sHLA-I associated with pancreatic cancer and disease
2) Confidence 0.72 Published 2001 Journal Hum. Immunol. Section Abstract Doc Link 11390036 Disease Relevance 1.31 Pain Relevance 0.05
We examined sHLA-I levels in the sera of patients with pancreatic cancer (n = 19), benign biliary disease and chronic pancreatitis (n = 20), hepatocellular carcinoma (n = 51), gallbladder cancer (n = 6), cholangiocellular carcinoma (n = 6), and in normal controls (n = 22), using enzyme-linked immunosorbent assay (ELISA).
Spec (examined) Gene_expression (levels) of sHLA-I associated with gallbladder neoplasms, hepatocellular cancer, pancreatic cancer, carcinoma, disease and chronic pancreatitis
3) Confidence 0.72 Published 2001 Journal Hum. Immunol. Section Abstract Doc Link 11390036 Disease Relevance 1.23 Pain Relevance 0.10
We determined a serum sHLA-I cutoff level for normal controls of 2000 ng/ml; serum levels of sHLA-I were higher than the cutoff in ten patients with pancreatic cancer, and serum levels of CA19-9 were lower than 37 IU/l in 9 of 14 patients; sensitivity and specificity were 88.2% and 85.5%, respectively.
Gene_expression (levels) of sHLA-I associated with pancreatic cancer
4) Confidence 0.56 Published 2001 Journal Hum. Immunol. Section Abstract Doc Link 11390036 Disease Relevance 1.70 Pain Relevance 0.07
A trend toward increased production of sHLA-I in the serum and CSF was observed in MS patients after immunomodulatory therapy [15].
Gene_expression (production) of sHLA-I associated with multiple sclerosis
5) Confidence 0.35 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 1.25 Pain Relevance 0.38
Typically, sHLA-I exists in very low quantities in the saliva, sweat, urine and/or tears of normal individuals, while sHLA-II is routinely detectable in all these body fluids [1].
Gene_expression (detectable) of sHLA-II in saliva
6) Confidence 0.35 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.99 Pain Relevance 0.30
Typically, sHLA-I exists in very low quantities in the saliva, sweat, urine and/or tears of normal individuals, while sHLA-II is routinely detectable in all these body fluids [1].
Gene_expression (exists) of sHLA-I in saliva
7) Confidence 0.30 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.90 Pain Relevance 0.22
Following this, 200 ul of peroxidase labeled anti-beta2 microglobulin (L368) for sHLA-I and L.2.03 Mab for sHLA-II were added to each bead and incubated for an additional hour at 45°C.
Gene_expression (labeled) of sHLA-I in L368
8) Confidence 0.30 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0 Pain Relevance 0.03
Preliminary evidence suggests that patients with systemic lupus erythematosus (SLE) are at increased risk of developing active disease in the presence of high sHLA-I levels in the saliva, while sHLA-II level has not been observed to be elevated in rheumatological diseases [11].
Gene_expression (levels) of sHLA-I in saliva associated with disease and systemic lupus erythematosus
9) Confidence 0.30 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.83 Pain Relevance 0.17
Scatter plots of distribution of saliva levels of sHLA-II of MS patients pre- and post-treatment with IFN-?
Gene_expression (distribution) of sHLA-II in saliva associated with multiple sclerosis
10) Confidence 0.30 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.10 Pain Relevance 0.05
Additionally, we did not observe any specific relationship between the baseline saliva sHLA-II levels and follow up values.
Gene_expression (levels) of sHLA-II in saliva
11) Confidence 0.30 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.23 Pain Relevance 0.11
Furthermore, we did not observe any discernible relationship between pre- and post-treatment saliva sHLA-II levels and subjects' clinical status.
Gene_expression (levels) of sHLA-II in saliva
12) Confidence 0.30 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.21 Pain Relevance 0.10
Following this, 200 ul of peroxidase labeled anti-beta2 microglobulin (L368) for sHLA-I and L.2.03 Mab for sHLA-II were added to each bead and incubated for an additional hour at 45°C.
Gene_expression (labeled) of sHLA-II in L368
13) Confidence 0.30 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0 Pain Relevance 0.03
Alterations in sHLA-I and sHLA-II levels in the serum and CSF of MS patients has been reported [12-14].
Gene_expression (levels) of sHLA-I associated with multiple sclerosis
14) Confidence 0.27 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 1.13 Pain Relevance 0.34
Saliva levels of sHLA-II were measured at baseline as well as at 3 and 6 months after treatment with IFN ?
Gene_expression (levels) of sHLA-II in Saliva
15) Confidence 0.27 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0 Pain Relevance 0
Recently, Fainardi et al [15] described a trend towards increased production of sHLA-I in the serum of patients with MS following the treatment with IFN ?
Gene_expression (production) of sHLA-I associated with multiple sclerosis
16) Confidence 0.27 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.54 Pain Relevance 0.18
All normal controls had detectable amounts of sHLA-II in the saliva with a mean value of 222 ± 18 unit/mL.
Gene_expression (detectable) of sHLA-II in saliva
17) Confidence 0.27 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.24 Pain Relevance 0.12
Alterations in sHLA-I and sHLA-II levels in the serum and CSF of MS patients has been reported [12-14].
Gene_expression (levels) of sHLA-II associated with multiple sclerosis
18) Confidence 0.27 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 1.13 Pain Relevance 0.34
All study subjects with RRMS had measurable amounts of sHLA-II in their saliva and in all subjects increases in saliva sHLA-II levels following treatment with IFN-?
Gene_expression (levels) of sHLA-II in saliva
19) Confidence 0.26 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.09 Pain Relevance 0.05
significantly increase sHLA-G1 and sHLA-G5 (non-classical HLA-class-I) expression by monocytes in vitro, IFN-?
Gene_expression (expression) of sHLA in monocytes
20) Confidence 0.23 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.60 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox